Research statistics

Relamorelin research: publications and trials

What has been published on Relamorelin: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Relamorelin works or is safe. For what it is and what the studies found, see the Relamorelin profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

34

Since 2011

Publications in 2026 so far

2

Through November 15, 2026

Human clinical research

29.4%

10 of 34 classified

Registered clinical trials

13

ClinicalTrials.gov

Randomized controlled trials

10

Publications reporting an RCT in people

Systematic reviews and meta-analyses

1

Preclinical studies

23.5%

6 animal · 0 in vitro · 2 computational

Records that only mention it

19

Not counted above

Status in the library: In clinical trials. Groups: Growth hormone axis.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Relamorelin publications by year and evidence

2011, Preclinical (animal, in vitro, computational): 1 of 12012, Human clinical research: 1 of 22012, Preclinical (animal, in vitro, computational): 1 of 22013, Human clinical research: 1 of 22013, Preclinical (animal, in vitro, computational): 1 of 22014, Preclinical (animal, in vitro, computational): 1 of 22014, Reviews and meta-analyses: 1 of 22015, Human clinical research: 2 of 52015, Preclinical (animal, in vitro, computational): 1 of 52015, Reviews and meta-analyses: 2 of 52016, Human clinical research: 2 of 32016, Other and not yet classified: 1 of 32017, Human clinical research: 2 of 62017, Reviews and meta-analyses: 4 of 62018, Human clinical research: 1 of 32018, Reviews and meta-analyses: 1 of 32018, Other and not yet classified: 1 of 32019, Reviews and meta-analyses: 1 of 12020, Human clinical research: 1 of 32020, Other and not yet classified: 2 of 32022, Reviews and meta-analyses: 1 of 12023, Reviews and meta-analyses: 2 of 22024, Preclinical (animal, in vitro, computational): 1 of 12026 (to date), Preclinical (animal, in vitro, computational): 2 of 2Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified024620112014201720202026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
201101001
201211002
201311002
201401102
201521205
201620013
201720406
201810113
201900101
202010023
202200101
202300202
202401001
2026 (to date)02002

Study types

Review11
Randomized controlled trial10
Animal study6
Editorial, letter or other4
Computational study2
Meta-analysis1

Research areas

From MeSH major topics. A paper can be in several areas.

Gastrointestinal27
Metabolic health11
Endocrinology9
Cardiovascular3
Immune system3
Neurological and mental health3
Obesity and weight management3
Musculoskeletal1

Registered clinical trials

1 of 7 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 7 · Terminated: 6
Phase 1: 3 · Phase 2: 5 · Phase 3: 5

TrialStatusPhaseStartedResults
Diabetic Gastroparesis Study 05NCT03786380 · 202 enrolledTerminatedPhase 32018-12Posted
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02NCT03426345 · 311 enrolledTerminatedPhase 32018-02Posted
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04NCT03383146 · 450 enrolledTerminatedPhase 32018-02Posted
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03NCT03420781 · 467 enrolledTerminatedPhase 32018-01Posted
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01NCT03285308 · 336 enrolledTerminatedPhase 32017-09Posted
Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy VolunteersNCT02466711 · 16 enrolledCompletedPhase 12015-06—
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic GastroparesisNCT02357420 · 393 enrolledCompletedPhase 22015-01Posted
Study to Evaluate the Effects of RM-131 in Patients With Chronic ConstipationNCT02137642 · 18 enrolledCompletedPhase 12014-08—
A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic ConstipationNCT01955616 · 18 enrolledTerminatedPhase 22013-09—
Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic ConstipationNCT01781104 · 48 enrolledCompletedPhase 22013-03—
Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia NervosaNCT01642550 · 20 enrolledCompletedPhase 22012-11—
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic GastroparesisNCT01571297 · 204 enrolledCompletedPhase 22012-04—
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic GastroparesisNCT01394055 · 20 enrolledCompletedPhase 12011-07—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis.

    Gastroenterology · January 31, 2019 · Meta-analysis · cited 171 times

    PMID 30711628 · DOI 10.1053/j.gastro.2019.01.249 · Reviews and meta-analyses

  2. Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.

    Alimentary pharmacology & therapeutics · April 17, 2020 · Randomized controlled trial · cited 41 times · open access

    PMID 32301137 · DOI 10.1111/apt.15711 · Human clinical research

  3. Treatment With a Ghrelin Agonist in Outpatient Women With Anorexia Nervosa: A Randomized Clinical Trial.

    The Journal of clinical psychiatry · January 1, 2018 · Randomized controlled trial · cited 74 times · open access

    PMID 29325236 · DOI 10.4088/jcp.17m11585 · Human clinical research

  4. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.

    Gastroenterology · July 29, 2017 · Randomized controlled trial · cited 157 times · open access

    PMID 28760384 · DOI 10.1053/j.gastro.2017.07.035 · Human clinical research

  5. A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned.

    Parkinsonism & related disorders · February 14, 2017 · Randomized controlled trial · cited 36 times

    PMID 28237854 · DOI 10.1016/j.parkreldis.2017.02.003 · Human clinical research

  6. Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.

    Neurogastroenterology and motility · June 9, 2016 · Randomized controlled trial · cited 57 times · open access

    PMID 27283792 · DOI 10.1111/nmo.12870 · Human clinical research

  7. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.

    Gastroenterology · April 4, 2016 · Randomized controlled trial · cited 134 times

    PMID 27055601 · DOI 10.1053/j.gastro.2016.03.038 · Human clinical research

  8. Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial.

    Digestive diseases and sciences · October 14, 2015 · Randomized controlled trial · cited 30 times

    PMID 26467700 · DOI 10.1007/s10620-015-3876-5 · Human clinical research

  9. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · May 19, 2015 · Randomized controlled trial · cited 49 times

    PMID 26001337 · DOI 10.1016/j.cgh.2015.04.184 · Human clinical research

  10. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · April 30, 2013 · Randomized controlled trial · cited 109 times · open access

    PMID 23639598 · DOI 10.1016/j.cgh.2013.04.019 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis.

    Gastroenterology · January 31, 2019 · Meta-analysis · cited 171 times

    PMID 30711628 · DOI 10.1053/j.gastro.2019.01.249 · Reviews and meta-analyses

  2. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.

    Gastroenterology · July 29, 2017 · Randomized controlled trial · cited 157 times · open access

    PMID 28760384 · DOI 10.1053/j.gastro.2017.07.035 · Human clinical research

  3. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.

    Gastroenterology · April 4, 2016 · Randomized controlled trial · cited 134 times

    PMID 27055601 · DOI 10.1053/j.gastro.2016.03.038 · Human clinical research

  4. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.

    Nature reviews. Gastroenterology & hepatology · September 22, 2015 · Review · cited 129 times · open access

    PMID 26392067 · DOI 10.1038/nrgastro.2015.163 · Reviews and meta-analyses

  5. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · April 30, 2013 · Randomized controlled trial · cited 109 times · open access

    PMID 23639598 · DOI 10.1016/j.cgh.2013.04.019 · Human clinical research

Latest publications

  1. Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets.

    Stem cells translational medicine · July 1, 2026 · Animal study · cited 0 times · open access

    PMID 42556326 · DOI 10.1093/stcltm/szag055 · Animal studies

  2. HighRes_Builder: improved access and modeling of noncanonical residues for protein structure prediction.

    Briefings in bioinformatics · May 1, 2026 · Computational study · cited 1 times · open access

    PMID 42218720 · DOI 10.1093/bib/bbag272 · Computational studies

  3. Peptide Drug Design Using Alchemical Free Energy Calculation: An Application and Validation on Agonists of Ghrelin Receptor.

    Journal of chemical information and modeling · June 5, 2024 · Computational study · cited 2 times

    PMID 38836743 · DOI 10.1021/acs.jcim.4c00414 · Computational studies

  4. Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety.

    Cureus · November 5, 2023 · Review · cited 6 times · open access

    PMID 38058346 · DOI 10.7759/cureus.48303 · Reviews and meta-analyses

  5. Diabetic Gastroparesis and its Emerging Therapeutic Options: A Narrative Review of the Literature.

    Cureus · September 7, 2023 · Review · cited 7 times · open access

    PMID 37814758 · DOI 10.7759/cureus.44870 · Reviews and meta-analyses

  6. Pharmacotherapeutic advances for chronic idiopathic constipation in adults.

    Expert opinion on pharmacotherapy · November 27, 2022 · Review · cited 13 times

    PMID 36408585 · DOI 10.1080/14656566.2022.2150076 · Reviews and meta-analyses

  7. Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis? Author's reply.

    Alimentary pharmacology & therapeutics · August 1, 2020 · Editorial, letter or other · cited 0 times · open access

    PMID 32656828 · DOI 10.1111/apt.15866 · Commentary and other

  8. Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis?

    Alimentary pharmacology & therapeutics · August 1, 2020 · Editorial, letter or other · cited 1 times · open access

    PMID 32656829 · DOI 10.1111/apt.15792 · Commentary and other

  9. Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.

    Alimentary pharmacology & therapeutics · April 17, 2020 · Randomized controlled trial · cited 41 times · open access

    PMID 32301137 · DOI 10.1111/apt.15711 · Human clinical research

  10. Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis.

    Gastroenterology · January 31, 2019 · Meta-analysis · cited 171 times

    PMID 30711628 · DOI 10.1053/j.gastro.2019.01.249 · Reviews and meta-analyses

Browse all 34 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: BIM-28131; Relamorelin; Relamorelina; Relamoreline; RM-131

((TITLE_ABS:"BIM-28131" OR CHEM:"BIM-28131" OR TITLE_ABS:"BIM28131" OR CHEM:"BIM28131") OR (TITLE_ABS:"Relamorelin" OR CHEM:"Relamorelin") OR (TITLE_ABS:"Relamorelina" OR CHEM:"Relamorelina") OR (TITLE_ABS:"Relamoreline" OR CHEM:"Relamoreline") OR (TITLE_ABS:"RM-131" OR CHEM:"RM-131" OR TITLE_ABS:"RM131" OR CHEM:"RM131")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Relamorelin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/relamorelin